Table 1.
HAI response by clinical trial and group assignment
|
VRC 306 |
VRC 310 |
|||||
|---|---|---|---|---|---|---|
| Group 1 (n=15) | Group 2 (n=15) | Group 3 (n=15) | Group 4 (n=15) | Group A (n=9) | Group B (n=11) | |
| Individuals with a four-times increase | 6 (40%) | 4 (27%) | 11 (73%) | 11 (73%) | 4 (44%) | 10 (91%) |
| Individuals with a post vaccination titre >1/40 | 6 (40%) | 4 (27%) | 11 (73%) | 11 (73%) | 4 (44%) | 10 (91%) |
| Before vaccination (GMT) | <1/10 | <1/10 | <1/10 | <1/10 | <1/10 | <1/10 |
| After vaccination (reciprocal GMT; 95% CI) | 33 (1–455) | 20 (3–126) | 103 (3–2827) | 248 (4–13 604) | 27 (12–63) | 206 (77–550) |
GMT=geometric mean tritre. Group 1 received H5N1 MIV at day 0 and week 4. Group 2 received H5 DNA at day 0 followed by H5N1 MIV at week 4. Group 3 received H5 DNA at day 0 followed by H5N1 MIV at week 24. Group 4 received two doses of H5 DNA (one at day 0 and the other at week 4) followed by H5N1 MIV at week 24. VRC 310 group A received H5N1 MIV at day 0 and week 24 and group B received H5 DNA at day 0 followed by an H5N1 MIV boost at 24 weeks.